.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,923,983

« Back to Dashboard
Patent 6,923,983 protects AXIRON and EVAMIST and is included in two NDAs. There has been one Paragraph IV challenge on Axiron. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has thirty-two patent family members in thirteen countries.

Summary for Patent: 6,923,983

Title: Transdermal delivery of hormones
Abstract:The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention
Inventor(s): Morgan; Timothy Matthias (Carlton North, AU), Bakalova; Margarita Vladislavova (Bundoora, AU), Klose; Karthryn Traci-Jane (Chelsea, AU), Finnin; Barrie Charles (Glen Iris, AU), Reed; Barry Leonard (Strathmore, AU)
Assignee: Acrux DDS PTY LTD (Victoria, AU)
Application Number:10/428,018
Patent Claim Types:
see list of patent claims
Compound; Delivery; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 22nd percentile
Forward Citations: 5th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010RXYes6,923,983► subscribeY TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYes6,923,983► subscribeY MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE)
Elan Pharma Intl Ltd
EVAMIST
estradiol
SPRAY;TRANSDERMAL022014-001Jul 27, 2007RXYes6,923,983► subscribeY FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,923,983

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPN8144Feb 19, 1996

Non-Orange Book Patents for Patent: 6,923,983

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,818,226 Dermal penetration enhancers and drug delivery systems involving same► subscribe
6,929,801 Transdermal delivery of antiparkinson agents► subscribe
6,916,487 Transdermal delivery of antiemetics► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,923,983

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria324865► subscribe
Austria410136► subscribe
Austria472997► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc